Menopause Hormone Therapy in the Management of Postmenopausal Osteoporosis

Cancer J. 2022 May-Jun 01;28(3):204-207. doi: 10.1097/PPO.0000000000000592.ABSTRACTThis narrative review analyzes the customization of menopause hormone therapy (MHT) for osteoporosis prevention and treatment in the context of the patients' age and menopausal age. In short, MHT is indicated in most women suffering from menopause before the age of 45 years except for breast cancer survivors. These women should be treated with MHT until the age of 50 years. For women who have entered menopause at around the age of 50 years, risks associated with MHT are low, and MHT is a safe option, provided there is an indication for it. We suggest that pursuing MHT entails different risks than initiating it, after the age of 60 years. In both cases, advantages and risks should be evaluated. We suggest using risk calculators to assess the magnitude of these risks and choosing regimens that entail the lowest breast and thrombosis risks.PMID:35594468 | DOI:10.1097/PPO.0000000000000592
Source: Cancer Journal - Category: Cancer & Oncology Authors: Source Type: research